Table 1. Clinicopathological characteristics in relation to p-4EBP1 expression status.
| Variable | Entire group (n = 36) | p-4EBP1 expression |
P value | |
|---|---|---|---|---|
| Low expression (n = 10) | High expression (n = 26) | |||
| Median age at surgery (y, range) | 29.0 (14.0–63.0) | 27.0 (15.0–63.0) | 30.0 (14.0–48.0) | 0.559 |
| Sex (n, %) | 0.763 | |||
| Male | 13 (36.1) | 4 (40.0) | 9 (34.6) | |
| Female | 23 (63.9) | 6 (60.0) | 17 (65.4) | |
| Clinical manifestation (n, %) | 0.900 | |||
| Incidental | 15 (41.7) | 4 (40.0) | 11 (42.3) | |
| Symptomatic | 21 (58.3) | 6 (60.0) | 15 (57.7) | |
| Laterality (n, %) | 0.137 | |||
| Left | 18 (50.0) | 7 (70.0) | 11 (42.3) | |
| Right | 18 (50.0) | 3 (30.0) | 15 (57.7) | |
| Operation (n, %) | 0.739 | |||
| Radical nephrectomy | 30 (83.3) | 8 (80.0) | 22 (84.6) | |
| Partial nephrectomy | 6 (16.7) | 2 (20.0) | 4 (15.4) | |
| Median tumor size (cm, range) | 5.7 (2.0–18.0) | 7.1 (3.0–18.0) | 5.5 (2.0–15.0) | 0.190 |
| T stage at presentation (n, %) | 0.293 | |||
| T1–T2 | 24 (66.7) | 8 (80.0) | 16 (61.5) | |
| T3–T4 | 12 (33.3) | 2 (20.0) | 10 (38.5) | |
| N stage at presentation (n, %) | 0.027 | |||
| N0 | 22 (61.1) | 9 (90.0) | 13 (50.0) | |
| N1 | 14 (38.9) | 1 (10.0) | 13 (50.0) | |
| M stage at presentation (n, %) | 0.274 | |||
| M0 | 28 (77.8) | 9 (90.0) | 19 (73.1) | |
| M1 | 8 (22.2) | 1 (10.0) | 7 (26.9) | |
| ISUP grade (n, %) | 0.842 | |||
| 1–2 | 8 (22.2) | 2 (20.0) | 6 (23.1) | |
| 3–4 | 28 (77.8) | 8 (80.0) | 20 (76.9) | |
| Adjuvant therapy (n, %) | 0.080 | |||
| None | 13 (36.1) | 6 (60.0) | 7 (26.9) | |
| Immunotherapy | 5 (13.9) | 2 (20.0) | 3 (11.5) | |
| Targeted therapy | 18 (50.0) | 2 (20.0) | 16 (61.5) | |
p-4EBP1, phosphorylated eukaryotic initiation factor 4E (eIF4E) binding protein 1; ISUP, International Society of Urological Pathology.